Hospira Furosemide Recall: Sterility and Vial Issues
Hospira recalls 63,900 vials of Furosemide Injection due to sterility risks and loose crimps. Check your NDC.
Stop using this now
Lack of Assurance of Sterility; possible loose crimp applied to fliptop vial
Contact the company
What happened, in plain English
Hospira Inc. is recalling Furosemide Injection USP (10 mg/mL) because the product lacks assurance of sterility and may have a loose crimp on the fliptop vial. This affects 63,900 vials distributed nationwide. The recall was issued on January 10, 2013. Read more at govinfonow.com/recall/48419-hospira-inc-recalls-furosemide-injection-usp-10-mg-ml-4.
Source Summary by GovInfoNow · govinfonow.com/recall/48419-hospira-inc-recalls-furosemide-injection-usp-10-mg-ml-4 · Updated October 13, 2026 · FDA enforcement record: FDA #D-169-2013
Cite this page
“Hospira Furosemide Recall: Sterility and Vial Issues.” GovInfoNow, updated October 13, 2026. https://govinfonow.com/recall/48419-hospira-inc-recalls-furosemide-injection-usp-10-mg-ml-4. Based on FDA recall #D-169-2013 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-169-2013%22&limit=1).
Why it’s dangerous
The lack of assurance of sterility means the injection could be contaminated, posing a risk of infection if administered. Additionally, a loose crimp on the fliptop vial may compromise the seal, further risking sterility and product integrity.
Who’s affected
Patients and healthcare providers who received Furosemide Injection USP with NDC 0409-6102-04 and lot number 18-099-DK. Healthcare facilities using these specific vials are also affected.
How to tell if you have this one
Look for Furosemide Injection USP (10 mg/mL) in 4 mL in 5 mL Fliptop Vials. Check for NDC 0409-6102-04 and lot number 18-099-DK on the packaging.
- Brand
Hospira- Category
Drug
What to do — step by step
Stop using the product
Do not administer or use any vials matching the recalled NDC and lot number due to sterility risks.
Contact your supplier
Reach out to your pharmacy or distributor for instructions on returning or disposing of the affected vials.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 21 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Questions people ask
How many vials are being recalled?
A total of 63,900 vials are subject to this recall.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-169-2013 (January 10, 2013) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-169-2013 to see it in context.
- Plain-language summary written by qwen3.6:35b-a3b on October 13, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.